Atlas Trials

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

Clinical trial NCT07540988 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07540988
Sponsor
Boehringer Ingelheim
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Interstitial Lung Diseases
Start date
2026-08-28
Primary completion
2028-12-05
Enrollment
466

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.